SAFETY/EFFICACY OF IV ANTI-D FOR TREATMENT OF THROMBOCYTOPENIA IN HCV

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This will be a prospective pilot study of the safety and efficacy of intravenous Anti-D for the treatment of significant thrombocytopenia prior to or during the treatment of hepatitis C infection (with peginterferon-based therapy) in HIV-positive and HIV-negative patients. Hypothesis: Intravenous anti-D will increase platelet counts above the threshold of 50,000/uL recommended for the initiation of peginterferon therapy. Intravenous Anti-D will increase platelet counts above the threshold of 50,000/uL recommended for the dose reduction of peginterferon therapy.